PBGENE-HBV
Chronic Hepatitis B Virus (HBV) Infection
Phase 1/2Active - ELIMINATE-B Trial; 13 patients dosed across 5 cohorts
Key Facts
Indication
Chronic Hepatitis B Virus (HBV) Infection
Phase
Phase 1/2
Status
Active - ELIMINATE-B Trial; 13 patients dosed across 5 cohorts
Company
About Precision BioSciences
Precision BioSciences leverages its novel ARCUS genome editing platform to create precise gene insertion, knockout, and repair therapies. The company has achieved significant clinical milestones, including FDA Fast Track and Orphan Drug designations for its lead programs, and has demonstrated early clinical safety and antiviral activity for PBGENE-HBV. Its strategy focuses on advancing its wholly-owned pipeline in genetic diseases while maintaining partnerships, such as with TG Therapeutics, to validate its platform in other therapeutic areas.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B Virus (HBV) Infection Drugs
| Drug | Company | Phase |
|---|---|---|
| IMC-I109V | Immunocore | Phase 1 |